Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML / MDS After HSCT

Multiple Cancer Types

This is a Phase 1, open-label, non-randomized, single and multiple dose escalation study designed to evaluate the safety and preliminary efficacy of administering Mana 312 to subjects with AML / MDS after allogeneic HSCT.
Leukemia, Myelodysplastic Syndrome, Phase I
I
Byrne, Michael
NCT04679194
VICCCTTP20107

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: